Known as human metapneumovirus (hMPV), this virus is one of the viruses that cause the common cold (upper respiratory ...

The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...

Request To Download Free Sample of This Strategic Report @ Catalysts of Market Growth: The buoyant growth trajectory of the global monoclonal antibodies market is propelled by a convergence of ...

Analysis - Five years on from the first news of Covid-19, recent reports of an obscure respiratory virus in China may ...

Data showing continued in vitro neutralizing activity of PEMGARDA™ (pemivibart) against XEC have been submitted to the U.S. Food and Drug Administration (FDA), with a timely update to the PEMGARDA ...

Legislation that would block hospitals from transfusing blood containing COVID-19 antibodies or “synthetic mRNA” would ...

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individualsKavigale (sipavibart; AZD3152) is a ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

Although numerous studies have shown men have more severe acute COVID cases and higher mortality than women, females in their 40s have up to a 45% higher risk of getting long COVID than men, according ...